MedTrace Logo

Soluble Immune Checkpoints in Intra-Abdominal Infections

NCT07689266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-07-08

No results posted yet for this study

Summary

Intraabdominal infections is a life-threatening syndrome with a high incidence and a significant economic burden. The early-stage cytokine storm and the late-stage immunosuppression contribute to the mortality of sepsis. Immune checkpoints expressed on lymphocytes and antigen-presenting cells (APCs) play a crucial role in the pathogenesis of sepsis by regulating immune dysfunction. Specific therapies targeting immune checkpoints have shown great potential in animal and preclinical studies, paving the way for further clinical research. In this study, the significance of serum immune checkpoints - sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-beta1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, and Galectin-9 - will be investigated in patients with intraabdominal infection.

Conditions

  • Intra Abdominal Infections

Interventions

DIAGNOSTIC_TEST

Soluble Immune checkpoint levels

Soluble Immune checkpoint levels of the groups before any treatments

Sponsors & Collaborators

  • Istanbul Training and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-12-31
Completion
2025-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07689266 on ClinicalTrials.gov